国金证券股份有限公司 关于浙江联盛化学股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：国金证券股份有限公司 | 被保荐公司简称：联盛化学 | | --- | --- | | 保荐代表人姓名：聂敏 | 联系电话：010-85142899 | | 保荐代表人姓名：张锋 | 联系电话：010-85142899 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2．督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江联盛化学股份有限公司（以下简称"公司"）第三届董事会第十次会议（以下 简称"本次会议"）于 2023 年 8 月 28 日在公司会议室以现场结合通讯的方式召开。会 议通知于 2023 年 8 月 18 日通过专人送出、邮件或传真等方式发出，会议应出席董事 8 人，实际出席董事 8 人。本次会议由公司董事长牟建宇女士召集和主持，公司监事、 高级管理人员列席了会议。本次会议的召集、召开及表决程序符合《中华人民共和国 公司法》《中华人民共和国证券法》等有关法律、行政法规、规范性文件、部门规章 及《浙江联盛化学股份有限公司章程》的相关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 证券代码：301212 证券简称：联盛化学 公告编号：2023-030 浙江联盛化学股份有限公司 第三届董事会第十次会议决议公告 （一）审议通过了《关于公司 <2023 年半年度报告>及其摘要的议案》 董事会认为公司 2023 年半年度报告及其摘要的编制符合相关法律法规及《公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥233,350,600.29, representing a 6.25% increase compared to ¥219,622,410.85 in the same period last year[4] - Net profit attributable to shareholders was ¥33,794,308.43, an increase of 85.09% from ¥18,258,381.70 year-on-year[4] - Basic earnings per share rose to ¥0.31, up 34.78% from ¥0.23 in the same period last year[4] - Net profit for Q1 2023 reached ¥33,805,783.03, up 68.5% from ¥20,060,843.88 in the same period last year[19] - Operating profit increased to ¥38,443,089.91, a rise of 63.3% compared to ¥23,547,646.61 in Q1 2022[19] - Total comprehensive income for Q1 2023 was ¥33,805,783.03, compared to ¥20,060,843.88 in the previous year, marking a 68.5% increase[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.31, up from ¥0.23 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥43,097,793.56, a significant increase of 844.55% compared to a negative cash flow of -¥5,788,404.68 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥43,097,793.56, a significant improvement from a negative cash flow of ¥5,788,404.68 in Q1 2022[21] - The net increase in cash and cash equivalents was ¥22,466,667.14, a 279.40% increase compared to a decrease of -¥12,523,509.37 in the previous year[9] - Cash and cash equivalents at the end of Q1 2023 totaled ¥273,129,358.57, an increase from ¥127,772,327.87 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,654,149,532.15, a slight increase of 0.32% from ¥1,648,907,339.15 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to CNY 1,654,149,532.15, a slight increase from CNY 1,648,907,339.15 at the beginning of the year[14] - Total liabilities decreased from CNY 303,585,791.80 to CNY 273,736,446.48, indicating a reduction of about 9.8%[16] - The company's total equity increased from CNY 1,345,321,547.35 to CNY 1,380,413,085.67, representing a growth of approximately 2.6%[16] Research and Development - Research and development expenses increased by 36.53% to ¥7,999,391.16, aimed at enhancing product competitiveness[8] - Research and development expenses rose to ¥7,999,391.16, up 36.5% from ¥5,859,191.13 year-over-year[18] - The company is actively engaged in research and development of new products and technologies, although specific details were not disclosed in the report[12] Shareholder Information - The number of common shareholders at the end of the reporting period was 9,691, with the largest shareholder holding 52.78% of the shares[11] - The company has a total of 57,000,000 shares held by the largest shareholder, 联盛化学集团, which represents a significant portion of the ownership structure[11] Inventory and Receivables - Inventory levels decreased from CNY 107,264,309.16 to CNY 77,704,492.65, a decline of about 27.5%[15] - Accounts receivable rose from CNY 130,926,297.97 to CNY 159,672,876.01, an increase of approximately 21.9%[14] Financial Expenses and Taxation - The company reported a significant decrease in financial expenses, with a net income of -¥2,476,599.69, compared to ¥1,865,161.69 in the same period last year, due to increased interest income from raised funds[8] - The company experienced a 152.07% increase in taxes and surcharges, amounting to ¥1,131,233.33, attributed to higher revenue[8] Operating Costs - Total operating costs decreased to ¥194,039,600.39 from ¥194,983,743.05, reflecting a reduction of 0.5%[18]

证券代码：301212 证券简称：联盛化学 公告编号：2023-018 浙江联盛化学股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 浙江联盛化学股份有限公司（以下简称"公司"）已于 2023 年 04 月 19 日在 深圳证券交易所网站（www.szse.cn）及巨潮资讯网(www.cninfo.com.cn)上披露了 《浙江联盛化学股份有限公司 2022 年年度报告》及《浙江联盛化学股份有限公 司 2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业 绩、发展战略等情况，公司定于 2023 年 05 月 05 日（星期五）15:00-16:00 在"价 值在线"（www.ir-online.cn）举办浙江联盛化学股份有限公司 2022 年度业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 会议召开时间：2023 年 05 月 05 日（星期五）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） ...

Financial Performance - The company's operating revenue for 2022 was ¥1,041,133,695.75, representing a 24.98% increase compared to ¥833,013,848.92 in 2021[18] - The net profit attributable to shareholders for 2022 was ¥182,965,402.93, a significant increase of 106.69% from ¥88,520,742.84 in the previous year[18] - The basic earnings per share for 2022 rose to ¥1.85, up 69.72% from ¥1.09 in 2021[18] - The total assets at the end of 2022 reached ¥1,648,907,339.15, an 88.08% increase from ¥876,682,063.24 at the end of 2021[18] - The net assets attributable to shareholders increased by 208.58% to ¥1,313,229,934.85 from ¥425,575,774.53 in 2021[18] - The weighted average return on equity for 2022 was 18.47%, down from 23.17% in 2021, indicating a decrease in profitability[18] - The company achieved a total operating revenue of CNY 1,041,133,695.75, representing a year-on-year growth of 24.98%[72] - The total profit reached CNY 21,874.38 million, an increase of 106.76% compared to the previous year[64] - The net profit attributable to shareholders was CNY 18,296.54 million, reflecting a growth of 106.69% year-on-year[64] Cash Flow and Investments - The net cash flow from operating activities for 2022 was negative at -¥5,026,134.96, a decline of 102.78% compared to ¥180,777,134.66 in 2021[18] - Operating cash inflow totaled CNY 1,025,322,525.02, an increase of 25.81% compared to CNY 814,981,650.79 in 2021[87] - Net cash flow from operating activities decreased by 102.78%, resulting in a net outflow of CNY 5,026,134.96, primarily due to increased use of bank acceptance bills for sales payments[87] - Investment cash inflow dropped by 91.11% to CNY 4,427,779.39, while investment cash outflow surged by 627.10% to CNY 561,907,065.78, leading to a net cash outflow of CNY 557,479,286.39, a decrease of 1,928.55%[87] - Financing cash inflow increased significantly by 1,718.86% to CNY 848,048,962.26, mainly due to funds raised from a public stock issuance[87] Research and Development - The company invested CNY 25.56% more in R&D, with 5 new patents granted, totaling 34 authorized patents by the end of 2022[65] - Research and development expenses rose by 25.56% to ¥32,940,383.29 in 2022, compared to ¥26,235,612.57 in 2021[81] - R&D investment amounted to ¥32,940,383.29 in 2022, representing a 25.5% increase from ¥26,235,612.57 in 2021[86] - The number of R&D personnel increased to 48 in 2022, a 9.09% rise from 44 in 2021[86] - The company aims to enhance product competitiveness through technology upgrades and optimization of existing production processes[85] Market and Industry Trends - The fine chemical industry in China is projected to grow from a market size of approximately CNY 5.5 trillion in 2021 to CNY 11 trillion by 2027, with a compound annual growth rate (CAGR) of 8% from 2016 to 2021[30] - The revenue of the chemical raw materials and products manufacturing industry increased from CNY 6.5 trillion in 2017 to CNY 9.1 trillion in 2022, with a CAGR of 11.50% from 2017 to 2022[32] - The pharmaceutical intermediate market in China is expected to exceed RMB 290 billion by 2026, driven by both domestic and global pharmaceutical market growth[38] - The global pesticide industry is experiencing an upward trend, with major multinational companies holding over 60% market share, indicating a favorable environment for leading raw material enterprises[39] - China's electronic chemicals market is projected to reach RMB 448 billion by 2026, with a compound annual growth rate of 6.45%[41] Risk Management - The company faces risks including macroeconomic fluctuations, raw material price volatility, and production safety risks, which may impact future performance[4] - The company emphasizes the importance of risk awareness for investors regarding future plans and strategies[4] - The company is actively addressing risks related to raw material price fluctuations by monitoring price trends and optimizing procurement strategies[133] - The company has implemented risk control measures for its financial derivative trading, focusing on hedging against exchange rate and interest rate risks[104] Corporate Governance - The company has established a complete and independent procurement, research and development, production, and sales system, ensuring operational independence from its controlling shareholder[155] - The company has a fully independent labor and personnel management system, with all senior management personnel exclusively working for the company and not holding positions in the controlling shareholder's enterprises[157] - The company has updated and revised 21 governance documents to enhance its governance structure, ensuring compliance with relevant laws and regulations[147] - The company emphasizes investor relations management, providing multiple communication channels for investors and actively responding to their concerns[154] - The company has established a strategic committee, audit committee, nomination committee, and compensation and assessment committee to support the board's decision-making process[150] Employee and Talent Management - The company has a total of 411 employees, with 274 in production, 48 in technical roles, and 67 in administration[190] - The company has established a competitive compensation system to attract and retain talent, including a long-term equity incentive plan for key management and technical personnel[191] - The company has a comprehensive training system in place, offering various training programs to enhance employee skills and professional development[192] - The company has a structured remuneration decision process based on performance evaluations and company operating results[177] Dividend Distribution - The company plans to distribute a cash dividend of ¥3.80 per 10 shares (including tax) based on a base of 108,000,000 shares[4] - The total distributable profit for the year was 339,860,116.31 CNY, with the cash dividend representing 100% of the profit distribution[195] - The company did not issue any bonus shares or increase capital from reserves during this distribution[197] - The company is in a growth phase and aims for a minimum cash dividend ratio of 20% in profit distribution[196] Production and Operations - The company has developed advanced technologies such as dehydrogenation-hydrogenation cycle technology and continuous production technology, facilitating its transition from manufacturing to intelligent manufacturing[45] - The production capacity utilization rates for key products are as follows: GBL at 57.99%, ABL at 67.29%, CPMK at 19.88%, IPA at 59.81%, E2 at 15.07%, PEO at 60.39%, and HDO at 4.53%[52] - The company has established long-term stable partnerships with renowned pharmaceutical companies, enhancing its market credibility and brand advantage[47] - The company has implemented continuous production for key products such as GBL, ABL, IPA, HDO, and PEO, with ABL production recognized as a "2022 Zhejiang Province First Batch Digital Workshop"[58]

Revenue and Profit - Revenue for Q3 2022 reached ¥252,459,768.99, an increase of 66.06% year-over-year[4] - Net profit attributable to shareholders was ¥58,684,970.20, a significant increase of 420.25% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥60,482,619.71, up 504.64% year-over-year[4] - Basic earnings per share for Q3 2022 was ¥0.54, reflecting a 285.71% increase from the previous year[4] - Revenue for the first nine months of 2022 reached CNY 774.80 million, a 31.55% increase compared to CNY 588.99 million in the same period of 2021[8] - Net profit for the first nine months of 2022 was CNY 146.99 million, representing a 97.09% increase from CNY 74.58 million in the same period of 2021[8] - The total profit for the first nine months of 2022 was CNY 171.32 million, a 102.11% increase compared to CNY 84.76 million in the same period of 2021[8] - The total profit for Q3 2022 was CNY 171,319,787.39, compared to CNY 84,764,259.86 in Q3 2021, representing a year-over-year increase of 102.3%[17] - The net profit attributable to shareholders of the parent company reached CNY 142,515,984.86, up from CNY 70,322,076.90 in the same period last year, marking a growth of 102.4%[17] Assets and Equity - Total assets as of September 30, 2022, amounted to ¥1,681,078,746.85, representing a 91.75% increase from the end of the previous year[4] - Shareholders' equity attributable to the company reached ¥1,272,832,360.98, a 199.08% increase compared to the previous year-end[4] - The company’s total assets increased by 426.92% in other non-current assets, reaching CNY 38.21 million, due to increased prepayments for projects and equipment[8] - Total assets as of September 30, 2022, were CNY 1,681,078,746.85, compared to CNY 876,682,063.24 at the beginning of the year, reflecting a growth of 91.5%[14] - Current assets totaled CNY 1,243,250,100.81, significantly up from CNY 472,459,926.95 at the start of the year, marking a 163.0% increase[13] - The company’s equity attributable to shareholders rose to CNY 1,272,832,360.98, up from CNY 425,575,774.53, an increase of 199.5%[15] Cash Flow and Financing - Cash flow from operating activities for the year-to-date was ¥15,863,771.42, showing a decline of 89.75%[4] - Cash and cash equivalents increased by 444.04% to ¥785,666,926.39, mainly due to funds raised from a public stock offering[7] - Cash flow from operating activities decreased by 89.75% to CNY 15.86 million, mainly due to an increase in accounts receivable[8] - Operating cash inflow totaled CNY 712,493,396.88, an increase from CNY 612,829,685.11 in the previous year, indicating a growth of 16.3%[19] - The net cash flow from operating activities was CNY 15,863,771.42, down from CNY 154,797,601.88 in the same quarter last year, showing a decline of 89.7%[19] - The company raised CNY 749,048,962.26 from investment activities, a significant increase compared to the previous year[19] - The net cash flow from financing activities was CNY 661,422,287.18, compared to a negative cash flow of CNY -53,689,501.44 in the same period last year[19] Costs and Expenses - Total operating costs amounted to CNY 602,229,041.28, up 19.4% from CNY 504,484,775.34 in the prior period[16] - Research and development expenses for the period were CNY 23,253,115.75, compared to CNY 20,533,558.99 in the previous period, indicating a 8.3% increase[16] Non-Recurring Items - The company reported a non-recurring loss of ¥1,797,649.51 for Q3 2022, primarily due to foreign exchange derivative investment losses[5] - The company reported a significant increase in investment income, rising 578.07% to CNY 1.68 million, attributed to gains from derivative financial instruments[8] Other Information - The company did not undergo an audit for the Q3 2022 report[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in the same period of 2021[13]. - The net profit attributable to shareholders for the first half of 2022 was RMB 150 million, up 20% from RMB 125 million in the first half of 2021[13]. - The company's operating revenue for the reporting period was ¥522,341,137.70, representing a year-on-year increase of 19.54% compared to ¥436,967,560.50[21]. - The net profit attributable to shareholders was ¥83,831,014.66, marking a significant increase of 41.99% from ¥59,041,824.64 in the same period last year[21]. - The total profit reached 100.12 million yuan, up 36.16% compared to the same period last year[47]. - The company reported a net cash flow from operating activities of -¥46,867,798.45, a decline of 250.38% compared to ¥31,165,551.17 in the previous year[21]. - The company’s basic and diluted earnings per share increased by 27.40% to ¥0.93 from ¥0.73 in the same period last year[21]. - The company has set a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth rate of 20%[13]. Investment and Development - The company plans to invest RMB 300 million in new product development and technology research in the upcoming year[13]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[13]. - The company plans to extend its BDO industrial chain towards ultra-pure electronic chemicals and biodegradable new materials, enhancing its position in the specialty fine chemical sector[29]. - The company is currently engaged in new projects, including ultra-pure electronic chemicals and biodegradable materials, with a total investment of ¥15.06 million in the reporting period[74]. - The company has filed for multiple patents, with two new patents related to α-acetyl-γ-butyrolactone and cosmetic-grade 1,2-hexanediol purification equipment[48]. - The company has 31 authorized patents, including 22 invention patents, showcasing its strong R&D capabilities[50]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by the end of 2023[13]. - User data indicates a 25% increase in customer base, growing from 10,000 to 12,500 active users[13]. - The company serves notable clients including Bayer Group and Syngenta, indicating strong market relationships and demand for its products[29]. - The company is focusing on expanding its customer base both domestically and internationally to reduce reliance on a limited number of clients[107]. Risk Management - The company faces risks related to raw material price fluctuations and macroeconomic volatility, which may impact future performance[4]. - The company is closely monitoring raw material prices, which include BDO, ethyl acetate, and others, to manage procurement costs effectively[102]. - The company has implemented risk control measures for its derivative investments to mitigate potential losses from currency fluctuations[94]. - The company is taking steps to hedge against foreign exchange risks due to its export-oriented business model, primarily denominated in USD[106]. Environmental and Safety Compliance - The company has implemented a comprehensive safety and environmental management system, enhancing its overall competitiveness[57]. - The company has obtained environmental impact assessments and pollutant discharge permits for all production projects, ensuring compliance with regulations[123]. - The company has established EHS departments and dedicated personnel to ensure compliance with environmental regulations and standards[120]. - The company has implemented an emergency response plan for environmental incidents, with regular drills and evaluations conducted[124]. - The wastewater treatment facility at Liansheng Chemical has a daily processing capacity of 300 tons, with no exceedances reported during the reporting period[120]. - The company emphasizes safety management, adhering to national safety production laws and regulations, with no major safety incidents reported during the reporting period[139]. Financial Position and Assets - The company's total assets increased by 102.87% to ¥1,778,503,593.26 from ¥876,682,063.24 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 185.25% to ¥1,213,957,713.04 from ¥425,575,774.53 at the end of the previous year[21]. - The company's cash and cash equivalents as of June 30, 2022, amount to ¥843,309,215.07, a significant increase from ¥144,413,440.96 at the beginning of the year[194]. - The total current assets reached ¥1,354,206,278.69, up from ¥472,459,926.95, marking a substantial growth of approximately 187%[194]. - The company's equity increased significantly to CNY 1,240,581,889.59 from CNY 453,968,753.49, marking a growth of 173.5%[196]. Corporate Governance - The company held 4 board meetings, 2 shareholder meetings, and 4 supervisory meetings during the reporting period, reviewing a total of 83 proposals[130]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[128]. - The company has not experienced any significant changes in the feasibility of the investment projects[87]. - The company has not engaged in any entrusted loans during the reporting period[95]. - The company has not made any changes to the use of raised funds during the reporting period[89]. Shareholder Information - The company completed its initial public offering of 27 million shares, increasing the total share capital from 81 million to 108 million shares[172]. - The company’s shareholding structure includes 76.29% of limited shares and 23.71% of unrestricted shares after the recent issuance[171]. - The total number of ordinary shareholders at the end of the reporting period is 18,894, with the largest shareholder, Liansheng Chemical Group Co., Ltd., holding 52.78% of shares, equating to 57,000,000 shares[181].

Financial Performance - The company's operating revenue for 2021 was ¥833,013,848.92, representing a year-over-year increase of 22.55% compared to ¥679,726,962.61 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥88,520,742.84, a decrease of 9.43% from ¥97,742,469.12 in 2020[20]. - The net cash flow from operating activities increased by 74.10% to ¥180,777,134.66 in 2021, up from ¥103,832,805.03 in 2020[20]. - The total assets at the end of 2021 were ¥876,682,063.24, reflecting a 19.21% increase from ¥735,394,998.95 at the end of 2020[20]. - The company's net assets attributable to shareholders increased by 25.72% to ¥425,575,774.53 at the end of 2021, compared to ¥338,514,778.12 at the end of 2020[20]. - The basic earnings per share for 2021 was ¥1.09, down 9.92% from ¥1.21 in 2020[20]. - The weighted average return on equity decreased to 23.17% in 2021 from 32.90% in 2020[20]. - The gross profit margin for the fine chemical industry was 21.60%, down 7.10% from the previous year[58]. - The company's overseas sales accounted for 51.87% of total revenue, with a year-on-year growth of 19.40%[56]. - The company reported a significant increase in operating costs, with total operating costs reaching CNY 653.10 million, up 34.77% year-on-year[58]. Risk Management - The company emphasizes the importance of risk awareness regarding macroeconomic fluctuations, raw material price volatility, exchange rate changes, and safety production risks[5]. - The company’s future plans and development strategies are subject to risks and do not constitute a commitment to investors[5]. - The company is facing risks from macroeconomic fluctuations and raw material price volatility, which could impact performance[93]. - The company is exposed to exchange rate fluctuations, particularly as its main business is export-oriented and primarily denominated in USD, which could affect performance if the RMB appreciates against the USD or EUR[94]. - The company is at risk of product price declines due to market supply and demand changes, which could lead to reduced gross margins and slower growth or declines in operating performance[95]. - The company must comply with increasingly stringent environmental and safety regulations, which could raise costs and impact profitability if compliance issues arise[95]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[4]. - The company has not faced any penalties from regulatory authorities in the past three years[119]. - The board of directors held a total of 7 meetings during the reporting period, with all members present at each meeting[127]. - The company has a structured remuneration decision process based on performance evaluations and company regulations[120]. - The company has maintained a consistent attendance record at board meetings, with no absences reported[127]. - The company has proposed to hold a temporary shareholders' meeting to discuss various matters, including financial guarantees[125]. Research and Development - The company has 44 R&D personnel and has obtained 22 invention patents and 7 utility model patents, focusing on technological innovation and product diversification[49]. - The company’s major R&D projects include the development of electronic-grade dimethyl carbonate and the optimization of 1,2-hexanediol process technology, both of which are expected to enhance competitiveness[69]. - The company aims to expand its product structure and enhance market competitiveness through various new synthesis technologies and process optimizations[70]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving production efficiency and sustainability[170]. Environmental Compliance - The company has implemented online monitoring systems for various pollutants, ensuring compliance with environmental standards[146]. - The company has established a biological deodorization facility to manage odor emissions effectively[147]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a focus on compliance and environmental responsibility[146]. - The company has committed to continuous improvement in environmental performance through regular assessments and updates to emergency plans[152]. Market Strategy - The company is positioned in the fine chemical industry, which is a strategic focus for national development and has shown rapid growth in recent years[31]. - The company anticipates that the profitability of the fine chemical industry will remain favorable despite recent cost pressures and supply chain challenges[32]. - The company aims to enhance its core competitiveness through innovation-driven strategies and digital transformation[34]. - The company is actively expanding its domestic and international markets to increase its market share of key products[52]. Shareholder Engagement - The company held three shareholder meetings during the reporting period, with a 100% investor participation rate[106]. - The company distributed a cash dividend of 2.05 CNY per 10 shares, totaling 22,140,000 CNY for the reporting period[138]. - The total cash dividend accounted for 100% of the profit distribution amount[139]. - The company has committed to maintaining a dividend payout ratio of at least 30% of net profits for the next three years[182]. Employee Development - The company has established a comprehensive training system for employee development, including various training programs[136]. - The company emphasizes employee rights protection, ensuring compliance with labor laws and providing competitive compensation and benefits[156]. - The total number of employees at the end of the reporting period is 412, with 219 in the parent company and 193 in major subsidiaries[134]. Financial Management - The company has implemented a new leasing accounting policy effective from January 1, 2021, which is not expected to significantly impact net profit, total assets, or net assets[192]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 6 years[192]. - The company has reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[188].

Financial Performance - The company's revenue for Q1 2022 was CNY 219,622,410.85, representing a 7.15% increase compared to CNY 204,962,316.07 in the same period last year[3] - Net profit attributable to shareholders decreased by 37.14% to CNY 18,258,381.70 from CNY 29,048,240.80 year-on-year[3] - The company's basic earnings per share decreased by 36.11% to CNY 0.23 from CNY 0.36 in the same period last year[3] - The total comprehensive income for the period was CNY 20,060,843.88, compared to CNY 31,202,509.65 in the previous period[20] - The net profit for the first quarter of 2022 was RMB 20,060,843.88, down from RMB 31,202,509.65 in the same quarter of the previous year, indicating a decrease of approximately 35.7%[19] Cash Flow - The net cash flow from operating activities was negative CNY 5,788,404.68, a decline of 116.88% compared to a positive CNY 34,293,393.97 in the previous year[3] - The net cash flow from financing activities was CNY 15,333,799.18, a 133.01% increase compared to a negative CNY 46,457,752.77 in the same period last year[9] - The net cash flow from investing activities was CNY -22,068,903.87, down from CNY 29,368,104.16 in the previous period[24] - Cash inflows from financing activities were CNY 57,000,000.00, an increase from CNY 30,009,151.77 in the previous period[24] - The company incurred cash outflows from operating activities totaling CNY 188,964,332.90, compared to CNY 123,856,079.99 in the previous period[24] Assets and Liabilities - Total assets increased by 11.91% to CNY 981,058,010.68 from CNY 876,682,063.24 at the end of the previous year[3] - The company's total liabilities increased to RMB 507,281,626.73 from RMB 422,713,309.75, reflecting a growth of approximately 19.9%[16] - The company's equity attributable to shareholders rose to RMB 443,580,942.81 from RMB 425,575,774.53, an increase of about 4.2%[16] - Cash and cash equivalents at the end of the period totaled CNY 127,772,327.87, compared to CNY 62,155,623.82 at the end of the previous period[24] Operational Metrics - Operating costs for the first quarter of 2022 were RMB 194,983,743.05, compared to RMB 171,203,472.54 in the previous year, reflecting a year-over-year increase of about 13.8%[18] - Accounts receivable increased by 32.29% to CNY 175,093,032.63, primarily due to an increase in receivables still within the credit period[8] - Inventory rose by 31.94% to CNY 102,207,515.15, attributed to an increase in stock levels of certain products[8] - Inventory levels increased to RMB 102,207,515.15 from RMB 77,465,274.25, marking a rise of approximately 31.8%[14] Financial Expenses - The company reported a significant increase in financial expenses, which amounted to CNY 1,865,161.69, compared to a negative CNY 295,452.50 in the previous year, marking a 731.29% change[9] Fundraising and Projects - The company raised a total of RMB 80,109.00 million from the issuance of 27 million A-shares at RMB 29.67 per share, with a net amount of RMB 72,703.07 million after deducting issuance costs[12] - The company plans to utilize the raised funds for projects including a 52.6 million tons/year electronic and specialty chemicals renovation project and the construction of ultra-pure electronic chemicals and biodegradable new materials[12]